These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 15765069)

  • 1. Cost-effectiveness data on biologics needed.
    Sheridan C; Katsnelson A
    Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069
    [No Abstract]   [Full Text] [Related]  

  • 2. Redesigner drugs.
    Dove A
    Nat Biotechnol; 2004 Aug; 22(8):953-7. PubMed ID: 15286643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomics: determining the value of drug therapy.
    Peterson C
    Healthplan; 1998; 39(3):44-50. PubMed ID: 10181751
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmaceutical industry financial performance.
    Goodman M
    Nat Rev Drug Discov; 2009 Dec; 8(12):927-8. PubMed ID: 19949398
    [No Abstract]   [Full Text] [Related]  

  • 5. [Germany's Novartis Chief proposes "More competition through decentralized contracts"].
    Kosche D; Färber L
    MMW Fortschr Med; 2010 Aug; 152(31-33):6-7. PubMed ID: 20828056
    [No Abstract]   [Full Text] [Related]  

  • 6. The quiet revolution.
    Nat Biotechnol; 2003 Jul; 21(7):715. PubMed ID: 12833072
    [No Abstract]   [Full Text] [Related]  

  • 7. Organic synthesis remains relevant in drug discovery.
    Mehrotra MM
    Nature; 2007 Oct; 449(7162):535. PubMed ID: 17914370
    [No Abstract]   [Full Text] [Related]  

  • 8. Maximizing exclusivity for drug products.
    French H
    Nat Rev Drug Discov; 2005 Sep; 4(9):709. PubMed ID: 16178117
    [No Abstract]   [Full Text] [Related]  

  • 9. [The European Union and drugs].
    Viala G; Campion MD
    Ann Pharm Fr; 1995; 53(4):184-7. PubMed ID: 7574273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
    Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
    Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacoeconomics of spiralling cancer drug costs - is there a viable solution?
    Alifrangis C; Krell J; Stebbing J
    Eur J Cancer; 2011 Jun; 47(9):1285-6. PubMed ID: 21550231
    [No Abstract]   [Full Text] [Related]  

  • 12. Market watch: Sales of biologics to show robust growth through to 2013.
    Goodman M
    Nat Rev Drug Discov; 2009 Nov; 8(11):837. PubMed ID: 19876035
    [No Abstract]   [Full Text] [Related]  

  • 13. Veterinary vaccines in an economic and sociopolitical context. The viewpoint of the veterinary pharmaceutical industry.
    Gug M
    Dev Biol Stand; 1992; 79():31-6. PubMed ID: 1286762
    [No Abstract]   [Full Text] [Related]  

  • 14. Weighing the outcomes.
    Russo MJ; Balekdjian D
    Nat Biotechnol; 2008 Feb; 26(2):173-82. PubMed ID: 18259169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biotech patents-business as usual?
    Lawrence S
    Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
    [No Abstract]   [Full Text] [Related]  

  • 16. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
    Martikainen J; Kivi I; Linnosmaa I
    Health Policy; 2005 Nov; 74(3):235-46. PubMed ID: 16226136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are predictive biomarkers of toxicity worth having? An economic model.
    Jones B; Smith DA; Schmid EF
    Xenobiotica; 2012 Jan; 42(1):4-10. PubMed ID: 21970747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century.
    Kweder SL
    Birth Defects Res A Clin Mol Teratol; 2008 Sep; 82(9):605-9. PubMed ID: 18704917
    [No Abstract]   [Full Text] [Related]  

  • 19. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 20. Market exclusivity for biologics.
    Wheadon DE
    N Engl J Med; 2010 Feb; 362(7):661; author reply 661-2. PubMed ID: 20164494
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.